Adial Pharmaceuticals, Inc vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| ADIL | JNJ | |
|---|---|---|
| Market Cap | $8.71 million | $624.74 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | $-7,770,762 | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| ADIL | JNJ | |
|---|---|---|
| P/E Ratio | — | 30.07 |
| Price / Book | 2.34 | 7.35 |
| Price / Sales | — | 6.38 |
ADIL leads on 1 of 1 valuation factors.
Profitability
| ADIL | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | -209.05% | 24.76% |
JNJ leads on 1 of 1 profitability factors.
Risk & Sentiment
| ADIL | JNJ | |
|---|---|---|
| Short Interest | 0.00% | 0.67% |
ADIL leads on 1 of 1 risk & sentiment factors.
Dig deeper: ADIL overview, ADIL financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.